Backlight Names Benjamin Desbois as Chief Operating Officer
1.8.2023 13:30:00 EEST | Business Wire | Press release
Global media and entertainment technology company Backlight today announced the appointment of Benjamin Desbois to chief operating officer (COO) of Backlight. Desbois joins Backlight from Telestream, a leading provider of solutions for media creation and production, where he had served as chief revenue officer since 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230801619740/en/
Global media and entertainment technology company Backlight today announced the appointment of Benjamin Desbois to chief operating officer (COO) of Backlight. (Photo: Business Wire)
“Benjamin is a media and entertainment industry veteran with proven success driving growth and scaling customer-facing functions including sales, sales engineering, professional services, and customer success,” said president and CEO of Backlight, Ben Kaplan. “This track record, combined with Benjamin’s deep experience working with strategic customers and partners, global teams and supporting M&A integration, makes him a terrific addition to the Backlight team.”
Benjamin Desbois brings more than 20 years of experience in media and entertainment technology and has a deep understanding of media workflows and customer needs. Prior to Telestream, he held several management positions at Avid Technology, most recently as vice president of sales for the Americas. Before Avid, Benjamin was general manager for North America at Dalet. Earlier in his career at Dalet, he held a range of product management, professional services and sales positions.
As a senior leader, Benjamin has become known for his collaborative and team-oriented leadership style and working effectively with executive teams on strategy, innovation, operational excellence, integration, HR and culture. His deep industry experience includes helping to acquire and integrate numerous media technology products and teams.
“Backlight’s compelling thesis and the momentum the company has built thus far is exciting,” said Benjamin Desbois. “I look forward to working with the talented Backlight team to expand our reach, accelerate growth and deliver incredible innovative solutions that help our customers maximize value in their respective fields.”
Benjamin is a graduate of L’Ecole Des Mines De Paris and resides in Miami, Florida.
About Backlight
Backlight is a global media technology company that dramatically improves every stage of the video and entertainment content lifecycle – from creation through monetization. Backed by $200M in funding from PSG, Backlight has acquired six leading media software companies since launching in 2021. Video-forward organizations solve their mission-critical business and operational challenges by partnering with Backlight’s two divisions: Backlight Creative and Backlight Streaming. Backlight Creative provides award-winning software solutions for secure and efficient media management, production tracking and creative collaboration including iconik, ftrack, Gem and Celtx. Backlight Streaming provides cloud-based OTT video streaming, content management, media production, hyperdistribution, and monetization software, including Zype and Wildmoka, to world’s most innovative publishers and broadcasters. For more information visit backlight.co.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230801619740/en/
Contact information
Backlight Corporate Communications | media@backlight.co
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release
Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o
Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a
DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom